Montelukast Teva (Montelukast Sodium)

Montelukast, the active ingredient in Montelukast Teva, is a leukotriene receptor antagonist presented as a tablet for oral use. It treats asthma, exercise‑induced bronchoconstriction and allergic rhinitis in adults and children.

GNH USA supplies Montelukast Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast is a leukotriene receptor antagonist used to manage respiratory and allergic conditions.

Asthma: reduces the frequency of asthma attacks and improves lung function. Exercise‑induced bronchoconstriction: prevents bronchospasm triggered by physical activity. Allergic rhinitis: alleviates nasal congestion, sneezing and itching associated with seasonal allergies.

Montelukast may cause a range of adverse reactions.

Common Side Effects: - Headache - Abdominal pain - Nausea - Dizziness - Fatigue

Serious or Rare Side Effects: - Angioedema or severe allergic reactions - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Eosinophilic granulomatosis with polyangiitis (Churg‑Strauss syndrome) - Hepatic injury - Mood changes, including suicidal thoughts

When prescribing Montelukast, consider the following precautions.

Assess asthma control before initiating: ensure the patient’s asthma is stable. Monitor for neuropsychiatric events: watch for mood changes or suicidal thoughts. Use caution in hepatic impairment: adjust therapy if liver function is compromised. Avoid in patients with known hypersensitivity to montelukast or excipients. Store at ambient temperature: keep in the original pack, protect from moisture and light.

Montelukast can interact with several medicines; review patient medication lists.

Major Interactions (Avoid): - Rifampin: may reduce plasma concentrations of montelukast. - Phenobarbital: may decrease montelukast effectiveness. - Ketoconazole: may increase montelukast levels, raising risk of adverse effects.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR; monitor coagulation parameters. - Beta‑agonists: additive bronchodilation effect; observe clinical response.